Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting ; volume:21 ; number:1 ; day:9 ; month:8 ; year:2023 ; pages:1-15 ; date:12.2023
Cost effectiveness and resource allocation ; 21, Heft 1 (9.8.2023), 1-15, 12.2023
- Creator
-
Malene B, Mikkelsen
Oyvind, Husby
Tor, Molden
David N, Mwaura
Jens, Olsen
Nanna V, Kristensen
Jeffrey, Vietri
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12962-023-00458-4
- URN
-
urn:nbn:de:101:1-2023110209191203097691
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Malene B, Mikkelsen
- Oyvind, Husby
- Tor, Molden
- David N, Mwaura
- Jens, Olsen
- Nanna V, Kristensen
- Jeffrey, Vietri
- SpringerLink (Online service)
Other Objects (12)
Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults
Effect of 23-valent pneumococcal polysaccharide vaccine on medical expenses in Japan
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
Severe polyserositis induced by the 13-valent pneumococcal conjugate vaccine: a case report
Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
Mortality reduction with 23-valent pneumococcal polysaccharide vaccine: a systematic review and meta-analysis
Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
Radiographically confirmed pneumonia in Malawian children and associated pneumococcal carriage after introduction of the 13-valent pneumococcal conjugate vaccine
Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults
Effect of 23-valent pneumococcal polysaccharide vaccine on medical expenses in Japan
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
Severe polyserositis induced by the 13-valent pneumococcal conjugate vaccine: a case report
Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
Mortality reduction with 23-valent pneumococcal polysaccharide vaccine: a systematic review and meta-analysis
Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
Radiographically confirmed pneumonia in Malawian children and associated pneumococcal carriage after introduction of the 13-valent pneumococcal conjugate vaccine
Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults
Effect of 23-valent pneumococcal polysaccharide vaccine on medical expenses in Japan
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
Severe polyserositis induced by the 13-valent pneumococcal conjugate vaccine: a case report
Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
Mortality reduction with 23-valent pneumococcal polysaccharide vaccine: a systematic review and meta-analysis
Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India